Get the Stockscreener App
50.30
1.20%
-0.60
Gsk Plc Adr stock is traded at $50.30, with a volume of 1.95M.
It is down -1.20% in the last 24 hours and down -11.29% over the past month.
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
See More
Previous Close:
$50.90
Open:
$50.45
24h Volume:
1.95M
Relative Volume:
0.38
Market Cap:
$101.00B
Revenue:
$43.93B
Net Income/Loss:
$8.53B
P/E Ratio:
13.15
EPS:
3.824
Net Cash Flow:
$5.74B
1W Performance:
-7.67%
1M Performance:
-11.29%
6M Performance:
+7.71%
1Y Performance:
+29.45%
1-Day Range:
$50.02
$50.65
1-Week Range:
$49.99
$52.63
52-Week Range:
$35.45
$61.70
Gsk Plc Adr Stock (GSK) Company Profile
Name
Gsk Plc Adr
Sector
Industry
Phone
-
Address
-
Compare GSK vs LLY, JNJ, ABBV, AZN, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GSK
Gsk Plc Adr
|
50.31 | 102.18B | 43.93B | 8.53B | 5.74B | 3.824 |
LLY
Lilly Eli Co
|
985.13 | 863.14B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
226.03 | 539.70B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
206.76 | 368.19B | 62.82B | 3.62B | 17.82B | 2.0331 |
AZN
Astrazeneca Plc
|
181.57 | 284.52B | 60.48B | 10.40B | 8.05B | 3.3297 |
MRK
Merck Co Inc
|
113.26 | 279.37B | 65.59B | 8.93B | 12.36B | 3.5532 |
Gsk Plc Adr Stock (GSK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-26 | Initiated | Citigroup | Neutral |
| Jan-06-26 | Downgrade | Barclays | Equal Weight → Underweight |
| Nov-25-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-03-25 | Downgrade | Berenberg | Buy → Hold |
| Apr-15-25 | Initiated | Exane BNP Paribas | Neutral |
| Feb-12-25 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-15-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Nov-12-24 | Downgrade | Jefferies | Buy → Hold |
| Oct-31-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-08-24 | Downgrade | UBS | Buy → Neutral |
| May-30-24 | Initiated | Goldman | Neutral |
| Mar-04-24 | Upgrade | Guggenheim | Neutral → Buy |
| Feb-13-24 | Upgrade | Citigroup | Neutral → Buy |
| Jan-23-24 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-16-24 | Resumed | UBS | Buy |
| Jan-03-24 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Mar-17-23 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-27-23 | Resumed | Goldman | Buy |
| Jan-03-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-11-22 | Downgrade | UBS | Neutral → Sell |
| Sep-15-22 | Upgrade | Credit Suisse | Underperform → Neutral |
| Sep-08-22 | Downgrade | Jefferies | Buy → Hold |
| Aug-05-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jul-21-22 | Resumed | Citigroup | Neutral |
| Feb-11-22 | Downgrade | DZ Bank | Buy → Hold |
| Nov-05-21 | Upgrade | Barclays | Underweight → Equal Weight |
| Jun-24-21 | Upgrade | Deutsche Bank | Sell → Hold |
| Mar-23-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-04-21 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-20-21 | Downgrade | Credit Suisse | Neutral → Underperform |
| Jan-15-21 | Initiated | Deutsche Bank | Hold |
| Nov-02-20 | Upgrade | Liberum | Hold → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Feb-12-20 | Downgrade | Shore Capital | Hold → Sell |
| Jan-16-20 | Downgrade | Barclays | Equal Weight → Underweight |
| Dec-02-19 | Initiated | SVB Leerink | Outperform |
| Nov-21-19 | Upgrade | UBS | Neutral → Buy |
| Oct-11-19 | Upgrade | Cantor Fitzgerald | Hold → Buy |
| Sep-03-19 | Resumed | Citigroup | Neutral |
| Sep-03-19 | Upgrade | Societe Generale | Sell → Buy |
| Aug-13-19 | Resumed | JP Morgan | Neutral |
| Jun-17-19 | Resumed | Morgan Stanley | Underweight |
| Mar-08-19 | Downgrade | Shore Capital | Buy → Hold |
| Feb-22-19 | Downgrade | UBS | Buy → Neutral |
| Jan-14-19 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| Dec-11-18 | Resumed | Jefferies | Buy |
| Oct-09-18 | Initiated | Guggenheim | Neutral |
| Aug-30-18 | Downgrade | Liberum | Buy → Hold |
| Apr-04-18 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Mar-22-18 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-09-18 | Upgrade | Kepler | Reduce → Hold |
View All
Gsk Plc Adr Stock (GSK) Latest News
Major holder in GSK (NYSE: GSK) reports 4.93% of voting rights - Stock Titan
GSK PLC Sponsored ADR Announces Quarterly Dividend of $0.44 (NYSE:GSK) - MarketBeat
GSK Stock Chart | GSK PLC-SPON ADR (NYSE:GSK) - ChartMill
Antibiotic Resistance Market to Grow at 5.4% CAGR Reaching USD 12.72 Billion by 2031, Driven by Rising Drug-Resistant Infections and Antimicrobial Innovation: Mordor Intelligence - GlobeNewswire Inc.
GSK Forecast, Price Target & Analyst Ratings | GSK PLC-SPON ADR (NYSE:GSK) - ChartMill
GSK out-licenses rights for rare liver disease drug to Alfasigma - MSN
GSK PLC Sponsored ADR (NYSE:GSK) Given Average Recommendation of "Reduce" by Brokerages - MarketBeat
GSK Fundamental Analysis & Valuation | Fair Value & Financial Strength | GSK PLC-SPON ADR (NYSE:GSK) - ChartMill
Farther Finance Advisors LLC Grows Stock Position in GSK PLC Sponsored ADR $GSK - MarketBeat
GSK PLC Sponsored ADR $GSK Shares Sold by Miller Howard Investments Inc. NY - MarketBeat
GSK plc (ADR) stock (GB0009252882): Why Google Discover changes matter more now - AD HOC NEWS
GSK PLC Stock Operating Data - GuruFocus
GSK PLC Sponsored ADR (NYSE:GSK) Sees Significant Growth in Short Interest - MarketBeat
GSK plc (ADR) stock (GB0009252882): Why its vaccines and specialty medicines strategy is suddenly wo - AD HOC NEWS
GSK Reports Promising Early Data For Experimental Cancer Drug - Sahm
GSK PLC Sponsored ADR $GSK Shares Acquired by Prime Capital Investment Advisors LLC - MarketBeat
Douglas Lane & Associates LLC Cuts Holdings in GSK PLC Sponsored ADR $GSK - MarketBeat
GSK plc (GSK) stock price, news, quote and history - Yahoo Finance Singapore
GSK plc (GSK) Stock Price, News, Quote & History - Yahoo! Finance Canada
GSK plc (ADR) Stock: ViiV Healthcare Ownership Restructured as Pfizer Exits, Strengthening GSK's HIV - AD HOC NEWS
GSK PLC Sponsored ADR (NYSE:GSK) Receives Average Recommendation of "Reduce" from Analysts - MarketBeat
GSK Stock Price, Quote & Chart | GSK PLC-SPON ADR (NYSE:GSK) - ChartMill
GSK plc (ADR) stock surges on FDA approval for Lynavoy as pipeline momentum builds for 2026 - AD HOC NEWS
GSK's Q4 earnings & sales beat estimates, stock up on '26 outlook - MSN
GSK PLC Sponsored ADR (NYSE:GSK) Short Interest Update - MarketBeat
FDA Broadens Access To GSK's Respiratory Syncytial Virus Shot For Younger High-Risk Adults - Sahm
GSK Out-Licenses Rights for Rare Liver Disease Drug to Alfasigma - Finviz
GSK PLC Sponsored ADR $GSK Shares Sold by Quantbot Technologies LP - MarketBeat
GSK (NYSE: GSK) files 2025 Form 20-F with audited 2025 financial statements - Stock Titan
Price Over Earnings Overview: GSK - Sahm
GlaxoSmithKline Pharma: Can India’s GSK Arm Still Reward US Investors? - AD HOC NEWS
GSK PLC Sponsored ADR $GSK Shares Sold by Kahn Brothers Group Inc. - MarketBeat
GSK PLC Sponsored ADR (NYSE:GSK) Short Interest Down 26.3% in February - MarketBeat
Gsk Plc Adr Stock (GSK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.65%
0.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):